Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Aspirin but not other NSAID drugs may help prevent cancer of the pancreas

Aspirin might be chemoprotective for pancreatic cancer claims a report in the Journal of the National Cancer Institute.

News image

fiogf49gjkf04

Aspirin is already known to reduce the risk of colon cancer, and laboratory studies have indicated that non-steroidal anti-inflammatory drugs (NSAIDs) may inhibit pancreatic cancer. Until now, however, epidemiological data to support this finding has been limited.

Now a prospective study conducted between 1992 and 1999, by members of the Division of Epidemiology at the University of Minnesota in Minneapolis, USA, has shed light on this topic, suggesting that aspirin may indeed prevent cancer of the pancreas.

Dr Kristin E. Anderson and colleagues assessed data on 28,283 women, aged 55 to 69, with the aim of examining the association between self-reported use of aspirin and other NSAIDs and the incidence of pancreatic cancer.

A total of 80 incident cases of pancreatic cancer were identified during 7 years of follow-up.

Following analysis of the data, the risk of pancreatic cancer was found to be 43% lower in women who took aspirin, or aspirin-containing products, compared to those women who did not.

There was a trend of decreasing risk of pancreatic cancer incidence with increasing frequency of aspirin use per week.

Compared with women who never took aspirin, women who took aspirin 2 to 5 times a week had a 53% lower risk of developing the cancer, and women who took it 6 times a week had a 60% lower risk.

Non-aspirin NSAID use was not associated with incident pancreatic cancer.

The researchers suggest that these data indicate that aspirin might be chemoprotective for pancreatic cancer.

While the mechanism by which aspirin could reduce the incidence of pancreatic cancer is not clear, it is thought to involve inhibition of expression of cyclo-oxygenase, but it probably involves other mechanisms as well, say the researchers.

Risk of pancreatic cancer - 43% lower regular aspirin takers
Journal of the National Cancer Institute

"In the study, other NSAIDs, such as ibuprofen, did not decrease the incidence of pancreatic cancer, perhaps reflecting differences in their mechanism of action", said Dr Anderson.

She cautioned, however, that the researchers did not have enough evidence to rule out that other NSAIDs may also reduce the risk of pancreatic cancer.

She said that the women in the study were asked in 1992 about their use of NSAIDs, when the drugs were not as widely used and some newer types had not yet been introduced.

Writing in the current issue of the British Medical Journal, in a news article, Dr Scott Gottlieb points out that the researchers did not collect data on the dose of aspirin the participants took or on the length of time that they were taking aspirin before enrolling in the study.

He adds that they looked only at current use, which precludes a comparison of short term and long term use, and that the homogeneity of the study population - postmenopausal women, 98% of whom were white - makes it difficult to generalize the results.

J Natl Cancer Inst 2002; 94(15): 1168-1171
19 August 2002

Go to top of page Email this page Email this page to a colleague

 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 21 February 2018 
Management of hemorrhoids in the USA
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 20 February 2018 
Complications and surveillance colonoscopies
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us